LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Home・Aandelen Lijst・Schrodinger Inc

Schrodinger Inc

Gesloten

SectorGezondheidszorg

12.04 -5.49

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.84

Max

12.62

Belangrijke statistieken
By Trading Economics
Inkomsten	10M -33M
Verkoop	-435K 54M
Winstmarge	-60.369
Werknemers	891
EBITDA	10M -31M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+86.44% upside

Dividenden
By Dow Jones
Volgende Winsten	6 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-686M 827M
Vorige openingsprijs	17.53
Vorige sluitingsprijs	12.04

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

23.27 / 26.13 Steun & Weerstand

Schrodinger Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 feb 2026, 23:53 UTC

Populaire aandelen

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27 feb 2026, 22:23 UTC

Acquisities, Fusies, Overnames

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

27 feb 2026, 17:55 UTC

Populaire aandelen

Toronto Stocks Decline, But Remain On Track for Weekly Gains

27 feb 2026, 23:46 UTC

Acquisities, Fusies, Overnames

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27 feb 2026, 23:33 UTC

Acquisities, Fusies, Overnames

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27 feb 2026, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

27 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

27 feb 2026, 21:30 UTC

Winsten

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27 feb 2026, 21:30 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27 feb 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27 feb 2026, 21:17 UTC

Winsten

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 feb 2026, 21:10 UTC

Acquisities, Fusies, Overnames

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27 feb 2026, 21:09 UTC

Acquisities, Fusies, Overnames

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27 feb 2026, 21:00 UTC

Winsten

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27 feb 2026, 20:31 UTC

Acquisities, Fusies, Overnames

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27 feb 2026, 20:24 UTC

Marktinformatie

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27 feb 2026, 20:23 UTC

Marktinformatie

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27 feb 2026, 20:12 UTC

Marktinformatie

Nike Seen With Further Challenges in China -- Market Talk

27 feb 2026, 19:44 UTC

Marktinformatie

Gold Caps Historic Month -- Market Talk

27 feb 2026, 19:39 UTC

Winsten

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 feb 2026, 19:38 UTC

Winsten

Earnings Could Push the Stock Market Higher. Too Bad About Everything Else. -- Barrons.com

27 feb 2026, 18:53 UTC

Acquisities, Fusies, Overnames

Largest U.S. Pension Takes Stake in a Hot Semi Stock, Buys More Nvidia and IonQ -- Barrons.com

27 feb 2026, 18:45 UTC

Winsten

Quantum Computing Is No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

27 feb 2026, 18:45 UTC

Marktinformatie

Bitcoin Stays Vulnerable in Choppy Geopolitical Situation -- Market Talk

27 feb 2026, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

27 feb 2026, 17:07 UTC

Winsten

Pemex Cuts 4Q Loss As Operating Results Improve

27 feb 2026, 17:00 UTC

Marktinformatie

Corn Rides Oil Momentum Higher -- Market Talk

27 feb 2026, 16:31 UTC

Marktinformatie

Canadian Economy Shows Resilience -- Market Talk

27 feb 2026, 16:17 UTC

Marktinformatie

Canada Economy is Struggling But More Rate Cuts Still a Long Shot -- Market Talk

27 feb 2026, 15:49 UTC

Winsten

Quantum Computing No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

Peer Vergelijking

Prijswijziging

Schrodinger Inc Prognose

Koersdoel

By TipRanks

86.44% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 22 USD 86.44%

Hoogste 30 USD

Laagste 18 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Schrodinger Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Schrodinger Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

23.27 / 26.13Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.